Imprimis Pharmaceuticals

Imprimis Pharmaceuticals is a publicly traded pharmaceutical company (NASDAQ: IMMY) based in San Diego.[1][2] It makes eye drops, compounded medicines and other products.

It manufactures a pyrimethamine and leucovorin compound which may offer a low-cost "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000% by Martin Shkreli and Turing Pharmaceuticals.[3][2]

Governance

In October 2015, Anthony Principi was elected to the company's board of directors.[4]

References

  1. ↑ "Imprimis Pharmaceuticals". imprimispharma.com. Impimis Pharma.
  2. 1 2 Bomey, Nathan (2015-10-23). "Drug company attempts $1 alternative to Daraprim". USA TODAY. Retrieved 2016-01-04.
  3. ↑ Kroll, David. "Imprimis' Fight Against Martin Shkreli Is Part Of A Larger Battle". Forbes. Forbes Publishing Group.
  4. ↑ Staff (1 October 2015). "People". Genetic Engineering & Biotechnology News (Paper). 35 (17). p. 49. Imprimis Pharmaceuticals elected Anthony J. Principi to its board of directors


This article is issued from Wikipedia - version of the 10/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.